Dewi Ni Luh Putu Yunia, Mariadi I Ketut, Pamungkas Kadek Mercu Narapati, Dewi Putu Itta Sandi Lesmana, Dewi Ni Nyoman Gita Kharisma, Sindhughosa Dwijo A
Gastroenterology and Hepatology, Centre Research for Alimentary and Hepatobiliary System, Denpasar, IDN.
Gastroenterology and Hepatology, Internal Medicine, Udayana University, Prof. Dr. I.G.N.G. Ngoerah Central General Hospital, Denpasar, IDN.
Cureus. 2024 Nov 1;16(11):e72823. doi: 10.7759/cureus.72823. eCollection 2024 Nov.
Background Mortality among patients with liver cirrhosis has recently increased in Indonesia. However, predicting the prognosis of patients hospitalized with liver cirrhosis remains a clinical challenge due to its variability and dependence on multiple factors. A simple and accurate method is required to identify high-risk patients. This study aims to build a predictive scoring system of in-hospital mortality in patients hospitalized with liver cirrhosis for clinical application. Methods A retrospective cohort study was done to collect data on patients with liver cirrhosis from November 2021 to January 2022. The study involved 110 patients hospitalized with liver cirrhosis. A multivariate regression analysis was performed to identify factors predicting in-hospital mortality. Each variable's score was determined by applying the (B/SE)/lowest B/SE formula. The overall probability was calculated using the equation 1/1+exp(-y). Analysis of area under the curve (AUC) was conducted to evaluate the sensitivity and specificity of the scoring system. Results A total of 52 patients (47.3%) died during hospitalization. The median age of the patient was 54.5 (30-82). A final model involving the presence of hepatic encephalopathy (HE) (p = 0.001), ascites (p = 0.025), diabetes mellitus type II (p = 0.003), acute kidney injury (p = 0.017), alanine transaminase (ALT) ≥ 68 (p = 0.001), creatinine level ≥ 1.25 (p = 0.011), and abnormal international normalized ratio (INR) (p = 0.047). The "ADRECIA" score was developed, consisting of ascites, type II diabetes mellitus, renal injury, hepatic encephalopathy, creatinine serum, INR, and ALT. The presence of HE and ALT ≥68 was scored as two, and the rest variables were scored as one. The best-discriminating value was at a cut-off point ≥ 2.5, with a sensitivity of 90.4%, and a specificity of 74.1%, and an AUC of 0.913 (95%CI: 0.862-0.964). The scoring system was categorized as low risk (score of zero to three) with a 1.4-43.6% probability of death and high risk (score of 4-9) with 74.7-99.9% probability of death. Conclusion This scoring system provides good accuracy in predicting in-hospital mortality in patients with liver cirrhosis. Therefore, treatment can be modified according to the score to reduce mortality rates.
背景 印度尼西亚肝硬化患者的死亡率最近有所上升。然而,由于肝硬化患者预后的变异性以及对多种因素的依赖性,预测肝硬化住院患者的预后仍然是一项临床挑战。需要一种简单而准确的方法来识别高危患者。本研究旨在建立一个用于临床应用的肝硬化住院患者院内死亡率预测评分系统。方法 进行一项回顾性队列研究,收集2021年11月至2022年1月期间肝硬化患者的数据。该研究纳入了110例肝硬化住院患者。进行多变量回归分析以确定预测院内死亡率的因素。每个变量的得分通过应用(B/SE)/最低B/SE公式来确定。总体概率使用公式1/1 + exp(-y)计算。进行曲线下面积(AUC)分析以评估评分系统的敏感性和特异性。结果 共有52例患者(47.3%)在住院期间死亡。患者的中位年龄为54.5岁(30 - 82岁)。最终模型包括肝性脑病(HE)的存在(p = 0.001)、腹水(p = 0.025)、II型糖尿病(p = 0.003)、急性肾损伤(p = 0.017)、丙氨酸转氨酶(ALT)≥68(p = 0.001)、肌酐水平≥1.25(p = 0.011)以及国际标准化比值(INR)异常(p = 0.047)。开发了“ADRECIA”评分,包括腹水、II型糖尿病、肾损伤、肝性脑病、血清肌酐、INR和ALT。HE的存在和ALT≥68评分为2分,其余变量评分为1分。最佳区分值为截断点≥2.5,敏感性为90.4%,特异性为74.1%,AUC为0.913(95%CI:0.862 - 0.964)。评分系统分为低风险(评分0至3分),死亡概率为1.4% - 43.6%,高风险(评分4至9分),死亡概率为74.7% - 99.9%。结论 该评分系统在预测肝硬化患者院内死亡率方面具有良好的准确性。因此,可以根据评分调整治疗以降低死亡率。